...
thar-img

Tharimmune Inc., Common Stock

THAR

NAQ

$2.09

-$0.09

(-4.13%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.24M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0.0357
Volume info-icon
This is the total number of shares traded during the most recent trading day.
11.04K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.45
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.83 L
$8.41 H
$2.09

About Tharimmune Inc., Common Stock

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameTHARSectorS&P500
1-Week Return0.46%-3.39%0.2%
1-Month Return-8.02%-1.92%2.72%
3-Month Return-27.09%-10.54%7.31%
6-Month Return-29.22%-4.47%10.44%
1-Year Return-71.67%4.06%27.53%
3-Year Return-99.83%0.94%30.88%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses994.54K1.52M3.21M6.88M9.46M[{"date":"2019-12-31","value":10.52,"profit":true},{"date":"2020-12-31","value":16.07,"profit":true},{"date":"2021-12-31","value":33.93,"profit":true},{"date":"2022-12-31","value":72.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(994.54K)(1.81M)(3.21M)(6.88M)(9.46M)[{"date":"2019-12-31","value":-99454000,"profit":false},{"date":"2020-12-31","value":-180835100,"profit":false},{"date":"2021-12-31","value":-320801700,"profit":false},{"date":"2022-12-31","value":-688193800,"profit":false},{"date":"2023-12-31","value":-945522000,"profit":false}]
Total Non-Operating Income/Expense(606.01K)(855.55K)170.10K(3.18M)272.25K[{"date":"2019-12-31","value":-222.59,"profit":false},{"date":"2020-12-31","value":-314.25,"profit":false},{"date":"2021-12-31","value":62.48,"profit":true},{"date":"2022-12-31","value":-1168.95,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(1.53M)(2.42M)(2.21M)(8.47M)(9.32M)[{"date":"2019-12-31","value":-152547400,"profit":false},{"date":"2020-12-31","value":-241737100,"profit":false},{"date":"2021-12-31","value":-220664300,"profit":false},{"date":"2022-12-31","value":-847318200,"profit":false},{"date":"2023-12-31","value":-931909400,"profit":false}]
Income Taxes-(42.67K)831.28K(228.49K)(15.26K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5.13,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-27.49,"profit":false},{"date":"2023-12-31","value":-1.84,"profit":false}]
Income After Taxes-(2.37M)(3.04M)(8.24M)(9.30M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-237470500,"profit":false},{"date":"2021-12-31","value":-303792000,"profit":false},{"date":"2022-12-31","value":-824469700,"profit":false},{"date":"2023-12-31","value":-930383000,"profit":false}]
Income From Continuous Operations(1.53M)(2.42M)(2.21M)(8.47M)(9.32M)[{"date":"2019-12-31","value":-152547400,"profit":false},{"date":"2020-12-31","value":-241737100,"profit":false},{"date":"2021-12-31","value":-220664300,"profit":false},{"date":"2022-12-31","value":-847318200,"profit":false},{"date":"2023-12-31","value":-931909400,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(1.53M)(2.42M)(2.21M)(8.47M)(9.32M)[{"date":"2019-12-31","value":-152547400,"profit":false},{"date":"2020-12-31","value":-241737100,"profit":false},{"date":"2021-12-31","value":-220664300,"profit":false},{"date":"2022-12-31","value":-847318200,"profit":false},{"date":"2023-12-31","value":-931909400,"profit":false}]
EPS (Diluted)--(0.45)(0.25)(10.57)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-45,"profit":false},{"date":"2022-12-31","value":-25,"profit":false},{"date":"2023-12-31","value":-1057,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

THAR
Cash Ratio 2.14
Current Ratio 2.35

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

THAR
ROA (LTM) -165.08%
ROE (LTM) -454.53%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

THAR
Debt Ratio Lower is generally better. Negative is bad. 0.43
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.57

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

THAR
Trailing PE 0.04
Forward PE NM
P/S (TTM) 0.00
P/B 1.07
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Tharimmune Inc. share price today?

Tharimmune Inc. (THAR) share price today is $2.09

Can Indians buy Tharimmune Inc. shares?

Yes, Indians can buy shares of Tharimmune Inc. (THAR) on Vested. To buy Tharimmune Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in THAR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Tharimmune Inc. be purchased?

Yes, you can purchase fractional shares of Tharimmune Inc. (THAR) via the Vested app. You can start investing in Tharimmune Inc. (THAR) with a minimum investment of $1.

How to invest in Tharimmune Inc. shares from India?

You can invest in shares of Tharimmune Inc. (THAR) via Vested in three simple steps:

  • Click on Sign Up or Invest in THAR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Tharimmune Inc. shares
What is Tharimmune Inc. 52-week high and low stock price?

The 52-week high price of Tharimmune Inc. (THAR) is $8.41. The 52-week low price of Tharimmune Inc. (THAR) is $1.83.

What is Tharimmune Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Tharimmune Inc. (THAR) is 0.0357

What is Tharimmune Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Tharimmune Inc. (THAR) is 1.07

What is Tharimmune Inc. dividend yield?

The dividend yield of Tharimmune Inc. (THAR) is 0.00%

What is the Market Cap of Tharimmune Inc.?

The market capitalization of Tharimmune Inc. (THAR) is $3.24M

What is Tharimmune Inc.’s stock symbol?

The stock symbol (or ticker) of Tharimmune Inc. is THAR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top